Ilomedin® 20 μg/1 ml

DRUG2 trials

Sponsors

Charite Universitaetsmedizin Berlin KöR, Charite Universitaetsmedizin Berlin KöR, Charite Universitaetsmedizin Berlin KöR

Conditions

Proximal humeral fracturebone fracture in patients identified as being at high risk of impaired fracture healing based on elevated pre-operative CD8+ T effector memory cells re-expressing CD45RA (TEMRA) levels

Phase 1

A phase I/IIa, prospective, mono-center, randomized, open labeled, controlled study to assess the safety and efficacy of applying Iloprost locally in the fracture site to promote bone healing in patients with proximal humeral fracture - ILOBONE

Active, not recruitingCTIS2024-512468-71-00

Charite Universitaetsmedizin Berlin KöR, Charite Universitaetsmedizin Berlin KöRProximal humeral fracture

Start: 2022-09-21Target: 30Updated: 2024-11-04

Phase 2

PRECISION Study: A phase II prospective, mono-center, randomized, double-blinded, controlled trial to assess the efficacy of local iloprost therapy to promote bone healing in patients at risk for fracture non-union

Not yet recruitingCTIS2026-527568-34-00

Charite Universitaetsmedizin Berlin KöRbone fracture in patients identified as being at high risk of impaired fracture healing based on elevated pre-operative CD8+ T effector memory cells re-expressing CD45RA (TEMRA) levels

Target: 60Updated: 2026-10-13